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Are we adequately prepared for the emergence of 
Salmonella enterica serovar Paratyphi A?
Typhoid fever is a life-threatening systemic disease 
caused by the bacterium Salmonella enterica serovar 
Typhi (S Typhi). Years of focused research have resulted 
in a detailed, but not complete, understanding of the 
disease caused by this organism. Diagnostics, host 
susceptibility, and vaccine responses need further research 
and investment, but recent technological advances 
in immunology and high-throughput genomics are 
providing new insights.1,2 Indeed, the burden of typhoid 
fever might be falling in parts of Asia, and the potential 
introduction of Vi-polysaccharide-conjugate vaccines 
could reduce the burden even more.3
Other Salmonella serovars and pathovars also cause 
invasive disease in human beings, which can be diﬃ  cult 
to distinguish clinically from typhoid. Invasive infections 
with S enterica serovars Typhimurium and Enteritidis in 
young children and also adults living with HIV in parts 
of sub-Saharan Africa have been reported.4 However, 
S enterica serovar Paratyphi (S Paratyphi) A, the main 
alternative cause of typhoid-like infections in most of 
the world, has received little attention. This knowledge 
gap has the potential to become an Achilles’ heel in the 
global battle against enteric (typhoid) fever.
At the turn of the millennium, S Paratyphi A caused 
about 20% of the global burden of enteric fever.5 In many 
areas, this proportion has steadily increased. In Patan 
Hospital in Kathmandu, Nepal, standardised surveillance 
of blood cultures during the past 10 years has shown 
annual increases in the proportions of individuals with 
S Paratyphi A. More than two-thirds of the culture-
conﬁ rmed cases of enteric fever are now caused by this 
serovar. Increases in the proportion of enteric fever cases 
caused by S Paratyphi A have also been reported in India, 
Pakistan, China, and Cambodia.6 In some locations, the 
proportion of enteric fever caused by S Paratyphi A is now 
greater than that caused by S Typhi. There is a real threat 
that S Paratyphi A could replace S Typhi as the main 
global cause of enteric fever. Clinicians often believe that 
S Paratyphi A infections are less severe than are those 
caused by S Typhi. However, in the largest comparison 
to date,7 no signiﬁ cant diﬀ erences were shown between 
disease severity, duration, or outcomes for infection 
caused by these organisms.
Both pathogens are transmitted through the faecal-
oral route by ingestion of contaminated food or water. 
Ingestion is followed by colonisation of the small intestine, 
invasion of the gastrointestinal mucosal surface, and 
dissemination throughout the body into the liver, spleen, 
and bone marrow. Crucially, S Typhi and S Paratyphi A 
infect only human beings, and no other Salmonella serovar 
entirely mimics the infection in other hosts. Much of 
the understanding of pathogenesis is derived from the 
mouse infection model of S enterica serovar Typhimurium, 
which does not adequately replicate human infection. 
The absence of a suitable animal model has impaired 
the ability of researchers to develop diagnostic tests that 
take into account the speciﬁ c biology of host–pathogen 
interactions. Researchers, therefore, rely almost solely on 
specimens collected from patients infected with these 
pathogens to understand the disease and investigate 
immunological responses.
S Paratyphi A could have a large eﬀ ect if 
Vi-polysaccharide-conjugate vaccines are introduced 
in Asia. The absence of the Vi-polysaccharide capsule 
in S Paratyphi A is the most important microbiological 
discrepancy between S Paratyphi A and S Typhi; vaccines 
based on Vi-polysaccharide do not provide any cross-
serovar immunity. At present no vaccines speciﬁ c to 
S Paratyphi A are available. Conjugate vaccines using the 
O antigen as the main immunological component are 
under development.8 However, these vaccines are some 
way from being licensed and made available to use in 
endemic locations. Whether they will provide suﬃ  cient 
protective eﬃ  cacy and herd immunity to be a cost-
eﬀ ective intervention for public health remains to be 
established.
In the absence of improvements in sanitation, clean 
water, and systematic vaccination, antimicrobial therapy 
for acute infection is the only intervention that can 
contribute to control of community transmission. 
Available data suggest that infections with S Typhi and 
S Paratyphi A both respond equally well to antimicrobials 
when the bacteria are susceptible.9 Unfortunately, 
antimicrobial resistance in all invasive Salmonella species 
is a growing threat, and S Paratyphi A seems to have a 
greater propensity than does S Typhi to develop resistance 
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to antimicrobials.10 Multidrug resistance and intermediate 
susceptibility to ciproﬂ oxacin is common in S Paratyphi A, 
and full resistance to ﬂ uoroquinolones, azithromycin, and 
ceftriaxone is of increasing concern. The world is not 
prepared for the emergence of S Paratyphi A. Although 
many lessons from research into S Typhi are applicable to 
S Paratyphi A, this neglected but emergent pathogen is a 
global health issue that needs the urgent attention of the 
enteric-fever research community.
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